| |||||||||||||
| Rating | Health Concerns |
|---|---|
![]() |
|
![]() |
Dysmenorrhoea (topical cream) |
Reliable and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary
studies suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but
minimal or no scientific evidence. For a supplement, little scientific support and/or minimal
health benefit. | |
Postmenopausal women have reduced production of progesterone. While this “deficiency” is normal, progesterone, including the natural forms of progesterone, has been found to relieve menopausal symptoms when used in combination with oestrogen replacement therapy.23
The proper amount of progesterone for a woman should be determined in consultation with a doctor. Some research with the natural, oral form of progesterone has used 200 mg per day.24 Progesterone is used in much lower amounts—such as 20–70 mg per day—by most doctors who prescribe topical natural progesterone. However, the ability of skin-applied progesterone to achieve effective levels in the body is the source of considerable debate.25 Although progesterone is a natural substance, oral progesterone supplements are available by prescription only. High-dose topical progesterone cream is also treated like a drug and requires a prescription. A few creams containing lower amounts of progesterone are sold without prescription.
Progesterone is a hormone and, as such, concerns about its inappropriate use have been raised. A physician should be consulted before using this hormone as a supplement. Few side effects have been associated with topical progesterone creams but can include skin reactions. Effects of natural progesterone on breast cancer risk remain unclear. Research has suggested both increased and reduced risk.
Synthetic progestins have many well-known side effects, including the increase of LDL (“bad”) cholesterol and the decrease of HDL (“good”) cholesterol. Other side effects reported with synthetic progestins include bloating, breast soreness, depression, and mood swings. Natural progesterone has been shown to have no adverse effect on HDL cholesterol levels.26 Overall, natural progesterone is considerably safer than progestins and is therefore preferred by many doctors in situations where either would be effective.27
At the time of writing, there were no well-known drug interactions with progesterone.
1. Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164–7.
2. Prior JC. Progesterone as a bone-trophic hormone. Endocr Rev 1990;11:386–98.
3. Lee JR. Osteoporosis reversal: the role of progesterone. Int Clin Nutr Rev 1990;10:384–91.
4. Riis BJ, Thomsen K, Strom V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987;156:61–5.
5. Leonetti HB, Longo S, Anasti JM. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225–8.
6. Martorano JT, Ahlgrimm M, Colbert T. Differentiating between natural progesterone and synthetic progestins: clinical implications for premenstrual syndrome and perimenopause management. Comp Ther 1998;24:336–9.
7. Freeman E, Rickels K, Sondheimer SJ, et al. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA. 1990;264:349–53.
8. Leonetti HB, Long S, Anasti JM. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obtstet Gynecol 1999;94:225–8.
9. Lobo RA, McCormick W, Singer F, Roy S. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 1984;63:1–5
10. Skegg DCG, Noonan EA, Paul C, et al. Depot medroxyprogesterone acetate and breast cancer; a pooled analysis of the World Health Organization and New Zealand studies. JAMA 1995;273:799–804.
11. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963–9.
12. Chang KJ, Fournier S, Lee TTY, et al. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785–91.
13. Söderqvist G, Isaksson E, von Schoultz B, et al. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Obstet Gynecol 1997;176:123–8.
14. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 1981;114:209–17.
15. Mohr PE, Wang DY, Gregory WM, et al. Serum progesterone and prognosis in operable breast cancer. Br J Cancer 1996;73:1552–5.
16. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 1981;114:209–17.
17. Plu-Bureau G, Lê MG, Thalabard MC, et al. Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. Cancer Detect Prev 1999;23:290–6.
18. Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217–21.
19. Rosano GMC. Presentation to the American Heart Association’s Scientific Sessions. New Orleans, Louisiana, 1996.
20. Martorano JT, Ahlgrimm M, Colbert T. Differentiating between natural progesterone and synthetic progestins: clinical implications for premenstrual syndrome and perimenopause management. Comp Ther 1998;24:336–9 [review].
21. Araghiniknam M, Chung S, Nelson-White T, et al. Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. Life Sci 1996;11:147–57.
22. Dollbaum CM. Lab analyses of salivary DHEA and progesterone following ingestion of yam-containing products. Townsend Letter for Doctors and Patients: Oct 1995, 104.
23. Hargrove JT, Maxson WS, Wentz AC, et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989;73:606–12.
24. Hargrove JT, Osteen KG. An alternative method of hormone replacement therapy using the natural sex steroids. Infert Repro Med Clin N Am 1995;6:653–74.
25. Cooper A, Spencer C, Whitehead MI, et al. Systemic absorption of progesterone from Progest cream in postmenopausal women. Lancet 1998;351:1255–56 [letter] and Lancet 1998;352:905–6 [comments].
26. Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol. 1985;151:746–50.
27. Hargrove JT, Osteen KG. An alternative method of hormone replacement therapy using the natural sex steroids. Infert Repro Med Clin N Am 1995;6:653–74.
| |||||||